Compare Enovix Corporation (ENVX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Mesoblast Limited — how do they compare? Enovix Corporation trades at $4.84 (market cap $1.11B), while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: Mesoblast Limited is far larger — about 2.1× Enovix Corporation's market cap, and Mesoblast Limited is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | MESO | |
|---|---|---|
Market Cap | $1.11B | $2.31B |
Sector | Technology | Technology |
52-Week High | $15.93 | $20.96 |
52-Week Low | $4.84 | $11.35 |
Enterprise Value | $1.13B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
